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of cells and tissues as they are perme-
ated with hierarchical blood vessels that 
provide oxygenation and nutrients and 
remove toxic metabolites. Besides pro-
moting multiple vital cell functions, vas-
cularization is a fundamental process 
involved in inflammation, tumor growth 
and metastasis, which is regulated by vas-
cular endothelial growth factor (VEGF) via 
interaction with its receptor (VEGFR).[2]
Current strategies to promote vas-
cularization are based on using growth 
factors (GFs), from simple delivery sys-
tems to highly engineered synergistic 
bioactive materials.[3,4] However, despite 
efforts, strategies based on GF delivery 
normally require the use of high concen-
trations to prevent their low stability and 
limited mode of action. For example, in 
a preliminary evaluation of phase I trial 
on the safety of topical administration of 
VEGF for the treatment of diabetic ulcers, 
72 µg cm−2 every 48 h for up to 6 weeks was considered “well 
tolerated” and no toxic despite the high doses used.[5] GFs pos-
sess high capability to induce intracellular signaling but they 
also play an essential role in tumor growth, invasion, and 
metastasis. Therefore, the use of supraphysiological doses of 
GFs may produce serious adverse side effects such as reported 
by the Food and Drug Administration (FDA) for recombinant 
Boron ion is essential in metabolism and its concentration is regulated by 
ion-channel NaBC1. NaBC1 mutations cause corneal dystrophies such as 
Harboyan syndrome. Here a 3D molecular model for NaBC1 is proposed and 
it is shown that simultaneous stimulation of NaBC1 and vascular endothelial 
growth factor receptors (VEGFR) promotes angiogenesis in vitro and in vivo 
with ultralow concentrations of VEGF. Human umbilical vein endothelial 
cells’ (HUVEC) organization into tubular structures is shown to be indicative  
of vascularization potential. Enhanced cell sprouting is found only in the presence 
of VEGF and boron, the effect abrogated after blocking NaBC1. It is demon-
strated that stimulated NaBC1 promotes angiogenesis via PI3k-independent 
pathways and that α5β1/αvβ3 integrin binding is not essential to enhanced 
HUVEC organization. A novel vascularization mechanism that involves  
crosstalk and colocalization between NaBC1 and VEGFR receptors is 
described. This has important translational consequences; just by adminis-
tering boron, taking advantage of endogenous VEGF, in vivo vascularization 
is shown in a chorioallantoic membrane assay.
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1. Introduction
Vasculogenesis, de novo development of new blood vessels 
from precursor cells, and angiogenesis, organization, and 
remodeling from pre-existing ones are both essential processes 
contributing to development of vascular systems.[1] Entirely 
developed vascular networks are essential for the functionality 
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human bone morphogenetic protein 2 (rhBMP2)-infuse,[6] or 
platelet-derived growth factor (PDGF) (Regranex).[7] Thus, alter-
native strategies that avoid the use of GFs or the use of very low 
dosages are needed to improve current therapies.
Angiogenesis is a tightly regulated process controlled by the 
dynamic interplay between GFs, extracellular matrix (ECM), 
and integrins.[8] Integrins are a family of transmembrane glyco-
proteins that activate after binding to a high repertoire of ECM 
components such as fibronectin (FN), collagen, laminin, fibrin-
ogen (FG), or other surface receptors, and mediate mechanical 
forces and biochemical signals—they are mechanosensors 
that regulate multiple cellular events.[9] The importance of the 
interplay between integrins and GF receptors has been exten-
sively demonstrated[10,11] as well as the interplay between GF 
receptors, integrins, and other transmembrane proteins such 
as urokinase plasminogen activator (uPA) receptor (uPAR).[12,13]
Ion channels are integral membrane proteins that con-
trol the ion flow through the cells, and besides regulating cell 
homeostasis, they can act as mechanosensors communicating 
extracellular signals to both the cytoplasmic environment[14] 
and integrins.[15] Only recently it has been reported the role of 
some calcium and potassium channels as potential therapeutic 
targets for cancer due to their importance in tumor vasculari-
zation.[16] Calcium channels play a major role in angiogen-
esis being part of signaling pathways linked to VEGF and its 
receptors VEGFR1/VEGFR2.[17] Sodium boron cotransporter 1 
(NaBC1 encoded by BTR1 or SLC4A11 gene) controls boron (B) 
homeostasis. Little is known about homeostasis and the func-
tion of this metalloid that plays a key role in the metabolism of 
plant and mammalian cells. We have previously reported that 
boron enhances myogenic differentiation.[18]
NaBC1 is unique among members of the SLC4 family 
of sodium-coupled bicarbonate transporter proteins. In the 
absence of borate, NaBC1 conducts Na+ and OH− (H+), while 
in the presence of borate, NaBC1 functions as an electrogenic 
Na+-coupled borate cotransporter.[19] Mutations in NaBC1 gene 
cause genetic diseases either affecting the cornea and eventually 
producing blindness (congenital hereditary endothelial cor-
neal dystrophy (CHED), Fuchs endothelial corneal dystrophy 
(FECD)) or a combined corneal dystrophy plus sensorineural 
deafness (Harboyan syndrome (HS)).[20,21]
Here, we report a novel mechanism by which boron induces 
angiogenesis in vitro and in vivo via simultaneous NaBC1 
and VEGFR activation using ultralow doses of soluble VEGF 
(<5 ng cm−2, compared to, e.g., 72 µg cm−2 administered in 
clinical trials) (Figure 1a).
2. Results
2.1. Boron Transporter (NaBC1): 3D Molecular Modeling  
and Expression
The protein encoded by the SLC4A11 gene (also named BTR1 
or NaBC1) was originally identified as a possible bicarbo-
nate transporter.[22] Notably, it was recently characterized as a 
sodium–boron cotransporter which is essential for mediating 
effect of boron in mammalian cells.[19] Multiple alignments 
of polypeptide sequences with representative members of 
bicarbonate transporters family (AE4, NBC1, and NDCBE1) 
are shown in Figure S1 (Supporting Information). Based on 
the best topology match, of ≈30%, in the PDB database cor-
responding to human erythrocyte band 3 protein SLC4A1, we 
predicted a 3D-protein structural model of Homo sapiens bicar-
bonate transporter-related protein NaBC1 (Figure 1b).
Most of the predicted transmembrane spans and intracel-
lular phosphorylation sites previously reported as targets for 
different protein kinases[22] are present in the protein sequence 
used for the predicted 3D model of NaBC1. Their relative 
positions are shown in Figure S1 (Supporting Information).
In order to confirm the expression of NaBC1 in our cellular 
system, we amplified human umbilical vein endothelial cells 
(HUVEC) NaBC1 messenger ribonucleic acid (mRNA) by poly-
merase chain reaction (PCR). We have used specific primers 
designed to avoid genomic amplification and located at the 
end and the beginning of two contiguous exons. Figure 1c 
shows the detected band of 238 nucleotides corresponding to 
mRNA of NaBC1 in all substrates. The presence of the bands 
observed in all conditions confirms that NaBC1 is ubiqui-
tously expressed in HUVEC, as in other cellular systems.[19]
NaBC1 transporter is boron specific and functions as an 
electrogenic obligated Na+-coupled borate cotransporter in the 
presence of borate. In the absence of borate, NaBC1 conducts 
Na+ and OH− (H+). As we have used sodium tetraborate dec-
ahydrate (borax) in this work, boron uptake by cells must occur 
via NaBC1 transporter, thus, via ion-channel activation instead 
of any other alternative transport mechanisms such as passive 
diffusion through the cell membrane, as for, e.g., boric acid.[23]
2.2. NaBC1 Stimulation Promotes HUVEC Organization
Having cells attached on a fibronectin-coated poly(l-lactic acid) 
(PLLA) surface, we examined the ability of boron to induce organ-
ization of endothelial cells into tubular-like structures in the pres-
ence or absence of very low soluble doses of VEGF (25 ng mL−1). 
Note that we have used PLLA surfaces in vitro to be consistent 
with the carrier used afterwards in vivo. Also, as it is known that 
3D-like environments are important to support vascularization,[3] 
after cell seeding on PLLA, samples were covered with a thin layer 
of fibrin matrix that provided cells with a simple 3D environment 
to support HUVEC sprouting and organization into cellular net-
works (Figure S2 in the Supporting Information shows HUVEC 
behavior in 2D conditions). After 6 days, cells cultured with 
boron (B2% and B5%) and VEGF supplemented media revealed 
enhanced network formation compared to cells cultured only with 
VEGF supplemented media (Figure 2a, first and second rows). 
Image analysis revealed statistical significant differences that 
support the hypothesis that boron promotes vascularization effec-
tively only in combination with VEGF (Figure 2b). Cell organi-
zation into tubular structures was quantified using parameters 
such as cell number, percentage of area covered by cells, number 
of aligned structures, total length of aligned structures, and the 
number of junctions (detailed process of image analysis quantifi-
cation is shown in Figure S3 in the Supporting Information).
Total cell number was similar in all conditions (B0%, B2%, 
and B5%), but with significant higher values when VEGF was 
added into the culture medium (Figure S4a—cell number, 
Adv. Biosys. 2019, 3, 1800220
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Supporting Information). Equally, the percentage of area cov-
ered by cells followed a similar trend, with comparable values 
among the three conditions that increase in cultures supple-
mented with VEGF (Figure S4a—percentage of area covered by 
cells, Supporting Information).
The number of aligned structures was similar for B0% 
and + VEGF; however, it strongly diminished for B2% and 
B5% when VEGF was added (Figure 2b, first row, number 
of aligned structures). Lower number of aligned structures 
involves more cocontinuity of tubular structures, with a higher 
number of junctions (Figure 2b, first row, number of junctions) 
and total length of structures (Figure S4a—total length, Sup-
porting Information). Overall, these parameters suggest higher 
levels of HUVEC organization when cells are cultured in the 
presence of boron and VEGF and suggest cooperation between 
boron transporter NaBC1 and VEGF receptor (Figure 1a).
2.3. NaBC1 Blocking Inhibits HUVEC Organization and Sprouting
As boron was only effective in combination with VEGF 
(Figure 2a, first and second rows), we have used media con-
taining ultralow doses of VEGF (25 ng mL−1) in all experiments 
from now on. We first investigated the role of boron by inhib-
iting the NaBC1 transporter using a specific antibody. Blocking 
NaBC1 resulted in reduced cellular organization (Figure 2a, 
third row) as quantified by image analysis (Figure 2b, second 
row); the number of aligned structures increased whereas 
their total length and the number of junctions diminished 
only for cells cultured with boron in the media (B2% and B5%; 
Figure 2b; Figure S4b, Supporting Information). Note that the 
total cell number and fraction of area covered by cells decreased 
in all conditions after blocking NaBC1 (Figure S4b, Supporting 
Information).
Adv. Biosys. 2019, 3, 1800220
Figure 1. The NaBC1 transporter. a) Schematic picture of events representing the role of boron and NaBC1 transporter, as well as other membrane 
receptors, in the regulatory crosstalk promoting vasculogenesis. b) Predicted structural 3D model of NaBC1 transporter based on the best topology 
match corresponding to human erythrocyte band 3 protein SLC4A1. The cytosolic and the anion exchanger domains are shown in green and yellow, 
respectively. The relative positions of both domains were placed arbitrarily. c) PCR amplification of NaBC1 mRNA of 238 nt extracted from HUVEC 
seeded onto different substrates with different amounts of boron. Left marker 50 bp, right marker 100 bp.
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We then looked at cell sprouting into the fibrin matrix that 
was used to cover cells and provide a supporting 3D environ-
ment.[3] Cell sprouting eventually occurred in all substrates 
(B0%, B2%, and B5%); however, it was enhanced only in the 
presence of VEGF and boron (B2% and B5%) (Figure 2c; 
Videos S1–S6, Supporting Information). Accordingly, blocking 
of NaBC1 inhibited this enhanced cell sprouting only in the 
presence of boron (B2% and B5%). This result demonstrates 
that boron activation of NaBC1 is key in promoting cell 
migration and matrix remodeling (Figure 2c).
2.4. NaBC1 Stimulation Compensates PI3k/Akt Signaling
We next investigated whether angiogenesis triggered by 
boron activation of NaBC1 involved downstream phospho-
rylation of PI3k/Akt, a pathway typically associated with 
VEGF signaling[24] (Figure 3a). In cell western assay showed 
that NaBC1 activation in combination with VEGF induced 
significantly Akt phosphorylation (Figure 3b). PI3k inhibi-
tion using 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-
4-one hydrochloride (LY-294002) strongly diminished HUVEC 
Adv. Biosys. 2019, 3, 1800220
Figure 2. HUVEC organization in 3D fibrin matrix environments. a) Fluorescence images of actin cytoskeleton (red) and nuclei (cyan) of HUVEC 
cultured during 6 days onto functionalized substrates (FN-coated) and with or without VEGF (25 ng mL−1) and boron (B0%, B2%, and B5%) present 
in the culture medium. B2% and B5% substrates showed higher degree of cell organization compared to B0% (first and second rows). Effects of NaBC1 
blocking on HUVEC organization. HUVEC cultured during 6 days onto functionalized substrates (FN-coated), with VEGF (25 ng mL−1) and boron 
(B0%, B2%, and B5%) present in the culture medium, after blocking with a specific NaBC1 antibody. NaBC1 blocking prevented cell organization on 
B2% and B5% conditions (third row). Scale bar represents 100 µm. b) Image analysis quantification of different parameters related to HUVEC organiza-
tion. Boron induces the formation of HUVEC network structures in combination with VEGF, leading to the minimal number of aligned structures (i.e., 
most of the structure are connected) and the higher number of junctions (first row). Image analysis quantification of parameters related to HUVEC 
organization after blocking the NaBC1 transporter (second row). The number of aligned structures augmented, the total length, and the number of 
junctions diminished suggesting impaired network organization only in the presence of boron. Statistics are shown as mean ± standard deviation. 
N = 10 images per condition from three different biological replicas. Data were analyzed by an ordinary one-way ANOVA test and corrected for multiple 
comparisons using Sidak’s analysis (p = 0.05). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c) Confocal 3D images of HUVEC sprouting into 3D 
fibrin matrix deposited onto functionalized substrates (FN-coated), with VEGF (25 ng mL−1) and boron (B0%, B2%, and B5%) present in the culture 
medium, after pre-incubation with specific NaBC1 antibody—actin cytoskeleton (red) and nuclei (cyan). Sprouting is not observed when NaBC1 is 
blocked. For 3D movies, see Videos S1-S6 (Supporting Information) of sproutings.
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organization (Figure 3c, B0%) but did not influence HUVEC 
alignment and fusion in the presence of boron (B2% and 
B5%, Figure 3c, magnification images). Image analysis 
showed that LY-294002 reduced significantly cell number in 
all cases notwithstanding percentage of area covered by cells, 
number and total length of structures, as well as number 
of junctions remained invariable in the presence of boron 
(Figure 3c graphics and Figure S3c, Supporting Informa-
tion). HUVEC organization triggered by boron stimulation 
of NaBC1 in the presence of LY-294002 suggests that active 
NaBC1 compensates PI3k inhibition, by stimulation of Akt 
signaling downstream of PI3k.
Adv. Biosys. 2019, 3, 1800220
Figure 3. Effects of PI3k inhibition on HUVEC organization. a) Schematic representation of mode of action of LY-294002 inhibitor. b) In cell western assay 
showing pAkt/Akt ratio on HUVEC after 45 min of culture. NaBC1 stimulation in the presence of VEGF resulted in significant enhancement of Akt phos-
phorylation. Statistics are shown as mean ± standard deviation. N = 4 biological replicas. Data were analyzed by an ordinary one-way ANOVA test and 
corrected for multiple comparisons using Dunnett analysis (p = 0.05). **p < 0.01, ****p < 0.0001. c) Images of actin cytoskeleton (red) and nuclei (cyan) 
of HUVEC cultured during 6 days onto functionalized substrates (FN-coated) with VEGF (25 ng mL−1) and boron (B0%, B2%, and B5%) present in the 
culture medium after 1 day of incubation with PI3k inhibitor. The upper row was considered as a culture control. Scale bar represents 100 and 50 µm for 
magnification images. Image analysis quantification of parameters related to HUVEC organization. PI3k blocking did not influence HUVEC network forma-
tion in the presence of boron. Statistics are shown as mean ± standard deviation. N = 10 images per condition from three different biological replicas. Data 
were analyzed by an ordinary one-way ANOVA test and corrected for multiple comparisons using Sidak’s analysis (p = 0.05). *p < 0.05, ****p < 0.0001.
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2.5. Effect of NaBC1 Activation in the Expression of Other 
Membrane Receptors Involved in Vascularization
We have shown that boron stimulates NaBC1 and, in the pres-
ence of ultralow doses of VEGF, promotes enhanced HUVEC 
organization and sprouting. Next, we investigated whether 
boron activation of NaBC1 influences the expression of other 
relevant receptors. Previous studies reported the critical 
role of integrin α5β1 and αvβ3 in angiogenesis and vascular 
development[25–27] and uPA—an ECM protease—and uPAR in 
endothelial cell migration in response to VEGF.[12]
Quantification of gene expression by quantitative PCR 
(qPCR) revealed enhanced integrin α5β1 and αvβ3 as well as 
uPAR with no effect on uPA levels (Figure 4a for B2% and 
B5%). Because uPAR,[13] β1,[28] and β3[29] integrins are known 
to cooperate with VEGFR to induce angiogenesis, our data sug-
gest a novel signaling mechanism that involves cooperation 
between NaBC1 (boron activated) and VEGFR (VEGF activated) 
Adv. Biosys. 2019, 3, 1800220
Figure 4. Gene expression of membrane receptors and effects of FN-binding domains in HUVEC organization. a) Analysis of relative mRNA expression 
of receptors involved in vascularization. The presence of boron enhanced the expression of α5β1 and αvβ3 integrins and uPAR. Statistics are shown 
as mean ± standard deviation. N = 5 different biological replicas. Data were analyzed by an ordinary one-way ANOVA test and corrected for multiple 
comparisons using Dunnett analysis (p = 0.05). *p < 0.05, **p < 0.01. b) Effects of FNΔRGD mutation in HUVEC organization. Fluorescence images of 
actin cytoskeleton (red) and nuclei (cyan) of HUVEC cultured during 6 days onto functionalized substrates mutant FN-coated, with VEGF (25 ng mL−1) 
and boron (B0%, B2%, and B5%) present in the culture medium. Impaired binding of α5β1 and αvβ3 integrins (cells grown onto FNΔRGD) resulted in 
lack of HUVEC organization on B0% substrates (magnification images showing formation or not of tubular-like network). Interestingly, the presence 
of boron compensates the integrin binding maintaining led to unaltered levels of HUVEC organization levels. For image analysis quantification of dif-
ferent parameters related to HUVEC organization, see Figure S5d in the Supporting Information. Scale bar represents 100 and 50 µm for magnification 
images. Data are represented as mean ± standard deviation. N = 10 images per condition from three different biological replicas.
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leading to enhanced expression of α5β1/αvβ3 integrins and uPA 
receptors (Figure 1a).
2.6. Simultaneous NaBC1 and VEGFR Signaling  
is Not α5β1/αvβ3 Dependent
To further investigate the interplay between NaBC1 and integrin 
receptors in HUVEC organization we used mutant fibronectins 
that compromise α5β1 and αvβ3 integrin binding. Mutations in 
FNRGE and FNΔRGD are located in the FN tenth type III module 
(FNIII10, RGD motif) and impair binding of α5β1 or α5β1/αvβ3 
respectively. Mutations in FNsyn are located in the synergy site 
(DRVPHSRN motif) located in the FN ninth type III module 
(FNIII9) in close proximity to the RGD motif. The synergy site 
binds α5β1 but not αv-class integrins; thus, mutations in this 
site results in low binding affinity for α5β1.[30]
Since we have used mouse cellular fibronectins (mcFNs), 
we first confirmed the same HUVEC organization using wild-
type mcFN (mcFNwt) compared to human plasma FN (hpFN) 
(Figure S5a,b, Supporting Information). Experiments with 
mutant mcFN confirmed that albeit enhanced expression of 
α5β1 and αvβ3 integrins, this is independent of vasculogenesis 
triggered by simultaneous NaBC1/VEGFR signaling. mcFNsyn 
led to unaltered HUVEC organization compared to mcFNwt, 
with still B2% and B5% presenting the best levels of tubular-like 
network formation even if α5β1 binding is prevented (Figure S5c, 
second row, Supporting Information). Using mcFNRGE and 
mcFNΔRGD (that prevent both α5β1 and αv binding) still allowed 
cells organization into tubular structures for conditions with 
B2% and B5% (Figure 4b; Figure S5c, third row, Supporting 
Information). The cell number and percentage of area cov-
ered by cells remained constant (compared to mcFNwt) using 
mcFNsyn, mcFNRGE, and mcFNΔRGD in all conditions (B0%, 
B2%, and B5%). However, using mcFNRGE and mcFNΔRGD the 
number of structures vanished only in B0% due to lack of cell 
alignment and fusion (Figure 4b, see insets; Figure S5d, Sup-
porting Information). Note that for mcFNRGE and mcFNΔRGD 
there is total lack of organization in absence of boron (B0%), 
so we were unable to quantify any parameters (Figure S5d, 
Supporting Information). In summary, simultaneous NaCB1 
and VEGFR activation allowed the maintenance of comparable 
HUVEC organization levels between mcFNwt and mcFNRGE/
mcFNΔRGD suggesting that enhanced VEGF/NaBC1 signaling is 
not dependent on α5β1 and αvβ3 integrin binding.
2.7. Simultaneous NaBC1/VEGFR Stimulation Induces Receptor 
Colocalization
To test whether simultaneous stimulation of NaBC1 and 
VEGFR occurs through a synergistic cooperation mechanism 
produced by physical protein–protein interaction, we tested 
NaBC1/VEGFR colocalization using DUOLINK proximity liga-
tion assay (PLA) system, which allows visualization of positive 
signals generated only if both receptors are within 40 nm dis-
tance. Figure 5a shows colocalization of NaBC1/VEGFR only 
after simultaneous stimulation with VEGF and boron. Little 
amounts of fluorescent dots were present also after VEGFR 
stimulation (B0%), but the dose-dependent increase of positive 
Adv. Biosys. 2019, 3, 1800220
Figure 5. Colocalization of NaBC1 and VEGFR. a) Images of nuclei (cyan) and colocalization dots (magenta) of HUVEC cultured during 3 h onto 
functionalized substrates (FN-coated) with VEGF (25 ng mL−1) and boron (B0%, B2%, and B5%) present in the culture medium. Scale bar represents 
10 µm. b) Image analysis quantification of colocalization dots of NaBC1/VEGFR. Colocalization levels increase as the stimulation of NaBC1 and VEGFR 
does. Statistics are shown as mean ± standard deviation. N = 30 images per condition from three different biological replicas. Data were analyzed by 
an ordinary one-way ANOVA test and corrected for multiple comparisons using Dunnett analysis (p = 0.05). **p < 0.01, ****p < 0.0001. c) Schematic 
representation of a NaBC1/VEGFR colocalization model, as a novel signaling mechanism, which involves cooperation between NaBC1 and VEGFR 
receptors after their respective activation to induce angiogenesis.
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signals in the B2% and B5% conditions suggested that costim-
ulation of both receptors is needed for effective colocalization 
(Figure 5b). Our results describe a novel protein–protein inter-
action between NaBC1 and VEGFR as a new mechanism for 
enhanced signaling in vascularization (Figure 5c).
2.8. Boron Induces In Vivo Vascularization
We have used PLLA, FDA-approved biodegradable material 
for a number of applications, as a support material for cells to 
grow in vitro and boron carrier to be released in in vivo. We 
used the chick embryo chorioallantoic membrane (CAM) assay 
to investigate the efficiency of NaBC1/VEGF signaling to pro-
mote vasculogenesis in vivo. CAM is an extra embryonic mem-
brane that mediates nutrient and gas exchanges during the 
living period of embryo. It has been commonly used in vivo 
to study both angiogenesis and antiangiogenesis in response to 
cells, tumors or soluble factors.[31] Figure 6a shows a schematic 
illustration of the concept of the system used for in vivo experi-
ments. Figure 6b shows the cumulative release from boron-
loaded PLLA solvent casted films, ≈100 mg L−1 for PLLA–B2% 
and 300 mg L−1 for PLLA–B5%. We used these values to calcu-
late the equivalent amount of boron added to the medium in 
Adv. Biosys. 2019, 3, 1800220
Figure 6. Boron release study and in vivo blood vessels formation on chick embryo chorioallantoic membrane (CAM). a) Scheme of boron-loaded 
PLLA release and boron transport inside the cell. b) Cumulative release of boron from PLLA–B2% and PLLA–B5%-loaded samples. Boron concentration 
was determined measuring A405 after azometin reaction. Final values were normalized with base absorbance values of bare PLLA. c) Representative 
stereomicroscope images of blood vessels formation after 96 h incubation with boron-loaded PLLA-functionalized substrates (PLLA–B2% and PLLA–
B5%). Control samples correspond to physiological vasculogenesis on CAM without material and bare PLLA. Representative masks used for vessel 
quantification obtained after image treatment are shown in the lower row. Boron-loaded substrates significantly enhanced vasculogenesis in vivo. Image 
analysis quantification of total blood vessels formation expressed as branches, and the number of junctions indicating the levels of connection between 
the vessels. Statistics are shown as mean ± standard deviation. N = 20 images per condition from six different biological replicas. Data were analyzed 
by an ordinary one-way ANOVA test and corrected for multiple comparisons using Tukey’s analysis (p = 0.05). *p < 0.05, ***p < 0.001, ****p < 0.0001.
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previous in vitro experiments (0.59 × 10−3 and 1.47 × 10−3 m 
as equivalent to PLLA–B2% and PLLA–B5%, respectively). We 
have used boron-loaded PLLA films that release boron within 
the first three hours after implantation (Figure 6b).
It is known that VEGF is already present in the chick embryo 
(chicken VEGF gene reference NM_001110355.1), and so we 
have used a system that releases boron, without any exogenous 
supplementation of VEGF.
PLLA films loaded with boron were deposited atop embryonic 
day 8 chicken CAM. After 96 h at 37.5 °C the total amount of 
blood vessels present was captured under a stereomicroscope. 
Figure 6c shows representative images of CAM vasculature and 
the correspondent masks created for image analysis. Boron 
delivery from PLLA (B2% and B5%)—in absence of exogenous 
VEGF—promoted neovascularization, with increased blood ves-
sels formation and new interconnections (Figure 6c). Together, 
these data demonstrate that bioengineered systems that release 
boron promote vasculogenesis through a mechanism that 
suggests NaBC1/VEGF simultaneous signaling using VEGF 
already present in the host.
3. Discussion
Vascularization is a complex multistep event essential for cell 
survival, embryonic development, tissue repair, and fertility. 
It also plays a key role in tumor growth, invasion, and metas-
tasis.[1,3] In general, in all tissues after injury, the cell micro-
environment turns hypoxic and loses the physiologic blood 
supply that acts as a source of oxygen, GFs, and cells needed for 
natural repair processes.
In regard to regenerative medicine, many tissue-engineered 
constructs had failed due to the inability to promote new vas-
culature.[32] Thus, there is a real need to develop strategies that 
induced formation of a functional vascular supply.[32–34] Current 
vascularization approaches involved GF delivery, cell delivery 
(or combined cell and GF delivery), as well as gene delivery[33] 
using biomaterials as carriers. The use of GFs for therapeutic 
vascularization has been limited due to their use at supraphysi-
ological doses that increases off-target side effects, including 
high cancer risk,[5,34,35] as occurs with rhBMP2-infuse bone 
graft[6] or PDGF (Regranex).[7]
Other recent reported strategies to promote vascularization in 
bone tissue engineering use bioactive glasses that contain a variety 
of ions (i.e., Cu2+, Co2+, Ca2+, Si4+, B3+, Eu3+, and Mg2+). Released 
ions from bioactive glasses are the central elements participating 
in osteogenic response. However, vasculogenic response is only 
well documented for Cu2+ and Co2+, while for Ca2+, Si4+, B3+, 
Eu3+, and Mg2+, even if described that promote angiogenesis to 
some extent, the mechanism is not well defined.[36] Indeed, bio-
active glasses present low stability and uncontrolled release of 
multiple components that can present possible risks of soft tissue 
calcification. The specific mechanisms that accelerate neovas-
cularization in the presence of the released ions from bioglass 
dissolutions have not yet been elucidated.[36]
Here, we present a simple approach that promotes vascu-
larization through a mechanism that involves simultaneous 
NaCB1 and VEGFR activation (Figure 1a), using boron to 
activate NaCB1 and promote the organization of HUVEC 
(Figure 2a,b). Even if boron is not physiologically as abundant 
as other ions such as calcium or zinc, it is still essential in cell 
metabolism and has the potential to trigger cell differentia-
tion in vitro.[18] Ion-channel NaBC1[19] is a unique and specific 
boron transporter that regulates the intracellular boron concen-
tration. NaBC1 contains 14 transmembrane spans and multiple 
predicted intracellular phosphorylation sites for protein kinase 
A, protein kinase C, and calmodulin kinase II[22] (Figure S1, 
Supporting Information). Here, we have predicted the NaBC1 
3D-protein structural model and detected its expression in 
HUVEC (Figure 1b,c).
Blocking NaBC1 in the presence of boron resulted in 
a reduction of cell organization, and the effect was more 
pronounced with higher concentrations of boron (see B5% in 
Figure 2a,b and also Figure S3b in the Supporting Information 
demonstrating that NaBC1 activation is essential for enhanced 
HUVEC organization. Further, we showed that NaBC1 activa-
tion stimulated endothelial cell sprouting, which was prevented 
after blocking NaBC1 in the presence of boron (B2% and 
B5%, Figure 2c; Videos S1–S6, Supporting Information). This 
finding demonstrates that NaBC1/VEGFR simultaneous acti-
vation stimulates cell migration. Nevertheless, the precise role 
of NaBC1 transporter in modulating cell migration requires 
further investigation.
Akt is an essential protein kinase involved in various sign-
aling cascades important in both normal cellular physiology 
and disease states. PI3K/Akt signaling pathway, specifically 
regarding endothelial cells, is activated (phosphorylated) by 
angiogenic GF and regulates downstream molecules involved 
in blood vessel growth and homeostasis controlling endothelial 
cell viability, NO-dependent vasodilation, and endothelial cell 
migration.[37] Our in cell western results suggested that NaBC1 
stimulation in combination with VEGF enhanced intracel-
lular signaling via Akt phosphorylation (Figure 3b). After PI3k 
inhibition with LY-294002, HUVEC organization remained 
unaltered only in boron-containing systems (B2% and B5%) 
(Figure 3c; Figure S4c, Supporting Information). The fact that 
boron activation of NaBC1 rescued the effect of PI3k inhibition 
in HUVEC organization demonstrated that NaBC1 is involved 
in angiogenesis, enhancing Akt phosphorylation independently 
of PI3k, probably throughout activation of uPAR (Figure 4a), 
suggesting a novel interplay among NaBC1/VEGFR and uPAR.
To obtain further insights into this mechanism, we used 
mutant FNs that impaired α5β1 and αvβ3 integrin binding.[30] 
HUVEC organization was abrogated when substrates were 
coated with mcFNRGE and mcFNΔRGD to prevent α5β1 and αvβ3 
binding (Figure 4b; Figure S5c,d, Supporting Information) but 
not in the presence of boron. It has been reported that VEGFR 
activate integrins through PI3k/Akt-dependent pathway,[38] and 
integrin activation modulates regulation of PI3k/Akt.[37,38] We 
show that either blocking PI3k or preventing integrin binding 
has no effect in NaCB1/VEGFR simultaneous signaling leading 
to enhanced vascularization in either case.
The fact that active NaBC1/VEGFR promoted HUVEC 
organization and sprouting in the absence of functional PI3k 
or α5β1/αvβ3 binding, suggests that the mechanism is working 
through alternative routes to PI3k signaling for Akt phospho-
rylation. One explanation could be the activation of mamma-
lian target of rapamycin (mTOR) pathway, another essential 
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metabolic road participating in vascularization, that after being 
stimulated by growth factors, increases Akt phosphorylation.[37] 
Our data suggest that uPAR participates in VEGF-induced 
cell migration of endothelial cells via interaction with VEGFR, 
as previously reported.[39] Then, blocking uPAR inhibits cell 
migration in a mechanism that is  extracellular signal-regulated 
kinases (ERK) but not PI3K/Akt-dependent.[13] Colocalization 
experiments demonstrate the physical interaction between 
NaBC1 and VEGFR (only positive signals appear if both pro-
teins are located within 40 nm) (Figure 5a,b). For the first 
time, we demonstrated that NaBC1 acts as a novel molecular 
sensor, as occurs with other ion channels, and interact with the 
cytoplasmic environment and other membrane receptors such 
as integrins and growth factor receptors.[15]
In summary, we demonstrated a novel function for NaBC1 
ion channel stimulating intracellular signaling in coordination 
with VEGFR to induce enhanced vascularization (Figure 5c). 
These findings are supported by in vitro data providing 
mechanistic insights and, importantly, by in vivo data using 
CAM assays in the absence of exogenous VEGF (Figure 6c). 
Boron-active NaBC1 acts in synergy with VEGF membrane 
receptor stimulating intracellular signaling that promotes 
vasculogenesis and angiogenesis. These results open new pos-
sibilities for biomedical applications maximizing the effects of 
critical target receptors avoiding off-target effects produced by 
the use of supraphysiological doses of GFs.
4. Conclusions
This work shows, for the first time, that in order to fully poten-
tiate the ability of biomaterials to control vascularization mech-
anisms, full attention needs to be given to the interplay between 
specific cell membrane receptors in order to mimic biological 
niche at molecular level. We hypothesize that simultaneous 
stimulation of NaBC1 and VEGF membrane receptors pro-
mote angiogenesis in the presence of ultralow doses of ligand 
(simulating physiological levels). We describe for the first time 
a novel vascularization mechanism that involves the crosstalk 
and colocalization between NaBC1 and VEGFR. We open new 
possibilities for the specific design of biomaterials at molecular 
level, avoiding the use of supraphysiological doses of growth 
factors causing adverse side effects and controlling critical 
target receptors instead.
5. Experimental Section
Material Substrates: PLLA (Cargill Dow) was dissolved at concentration 
of 2% (w/v) in chloroform. Borax 10 Mol (Na2B4O7·10H2O) (Borax 
España S.A) was used to load materials and dissolved in the culture 
medium for all experiments performed. For abbreviation hereafter, 
it will be designated as boron. Different solutions of PLLA 2%, 
containing 2% and 5% of boron in relation to total mass of polymer 
(mT = mPLLA + mboron), were performed in continuous stirring to 
prepare polymer sheets by the solvent casting method. After overnight 
chloroform evaporation, obtained films were dried in vacuo at 40 °C 
during 4 h and die-casted in 12 or 25 mm diameter substrates. These 
PLLA films (solvent casting) were used for in vivo experiments, and 
incorporated boron within the material.
PLLA 2% solution was used for substrate preparation of thin films by 
spin coating on cleaned glass cover slips for 30 s at 3000 rpm. Samples 
were dried at 60 °C in vacuo during 4 h.
Boron-Release Quantification: The in vitro release of boron was 
performed immersing different boron-loaded solvent-casted films 
(PLLA–boron-loaded 2% and 5%) in 1 mL of Dulbecco’s phosphate-
buffered saline (DPBS) (Sigma-Aldrich). PLLA was used as a control. 
Short terms accumulative release studies (maximum time 180 min) 
were performed removing a 40 µL aliquot from the medium every 
10 min. A long-term release study was previously performed by 
describing that major release was produced during the first three hours 
of culture.[18]
Reaction of boron present in the 40 µL aliquots with azometin 
(Sigma-Aldrich) in acid medium (KAc/HAc buffer pH 5.2) originated a 
colorimetric reaction measured at 405 nm in a Victor III (Perkin Elmer) 
device. Standards for calibration were prepared at concentrations of 0, 
0.2, 0.3, 0.5, 1, 1.5, 2, 5.2, and 52 mg mL−1 of boron.
Mutant Fibronectin Production: Mutant FNs were obtained through 
different procedures in dependence of the different mutations. Due to 
the embryonic lethality of the deletion, homozygous FNΔRGD/ΔRGD and 
FN+/+ fibroblasts were generated from 3.5 days old (E3.5) blastocysts. 
The embryonic stem cells were induced to differentiate into fibroblasts 
after culturing in Dulbecco’s modified Eagle’s growth medium (DMEM, 
ThermoScientific) with 10% of fetal calf serum (FCS, ThermoScientific) 
and 1% dimethyl sulfoxide (DMSO, Sigma-Aldrich), immortalized by 
retroviral transduction of the SV-40 large T antigen, and cloned. The 
cell lines FNsyn/syn and FNRGE/RGE were derived from E9.0 homozygous 
knock-in embryos[30] and immortalized by the same procedure. All the 
cells were grown and maintained in DMEM medium with 10% fetal 
bovine serum (FBS, ThermoScientific) and 1% penicillin–streptomycin 
(GIBCO).
To purify mouse cellular fibronectin (mcFN), fibroblasts were grown 
until 100% confluence in DMEM with 10% FCS. Then, the medium was 
removed and washed three times with a serum replacement medium 
(SRM: 46.5% AIM-V, Life Technologies), 5% Roswell Park Memorial 
Institute medium (RPMI) (Life Technologies), and 1% nonessential 
amino acid (NEAA) solution (Sigma-Aldrich) and left overnight. The 
medium was again discarded and replaced by fresh SRM and collected 
every 2 days. cFNsyn/syn, cFNΔRGD, cFNRGE, and cFNwt were purified from 
the cell-conditioned SRM media as described previously with gelatin-
Sepharose columns affinity chromatography.
Substrates’ Functionalization: In all experiments, except the ones 
performed with mutant FN matrices, FN (Sigma-Aldrich) from hpFN 
was used as ECM protein. After sterilizing the samples with UV for 
30 min, substrates were coated with FN solution for a concentration 
of 20 µg mL−1 in DPBS during 1 h at room temperature (RT). The 
quantification of surface density of adsorbed FN,[18] obtaining similar 
values for all boron-loaded or PLLA bare substrates disregarding any 
influence of boron on FN adsorption, was reported previously.
Wild-type and different mutant mcFNs were used for substrate 
coatings at 20 µg mL−1 following the same procedure as hpFN.
HUVEC culture and Organization: HUVEC (Cellworks) were routinely 
maintained in human large vessel endothelial cell basal medium 
(HLVEC) supplemented with serum/antibiotics (Cellworks). Only cells 
between passages from 1 to 9 were used, and they were subcultured 
once a week before reaching confluence. In all experiments, cell-
seeding density was 10.000 cells cm−2. For HUVEC organization, cells 
were seeded over hpFN or mutant mcFN-coated substrates during 
24 h at 37 °C and 5% CO2. After that, a fibrin 3D matrix composed 
of 20 mg mL−1 FG(Enzyme Research Laboratories), 50 U mL−1 of 
thrombin (Sigma-Aldrich), and 1.2 mg mL−1 of aprotinin (Sigma-
Aldrich), all dissolved in HLVEC medium in absence of serum, was 
added. After 1 h at 37 °C to allow complete FG clotting, 3D matrix was 
covered with HLVEC complete media supplemented with 25 ng mL−1 
of VEGF (R&D Systems) and boron (0.59 × 10−3 or 1.47 × 10−3 m, 
corresponding to the equivalent amount of boron in PLLA–boron 
2% and 5% samples, respectively) where required. Cultures were 
maintained during 6 days.
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In Cell Western: For evaluation of Akt phosphorylation, in cell western 
quantification was used. HUVEC (10.000 cells cm−2) were seeded onto 
hpFN-coated substrates during 1.5 h at 37 °C and 5% CO2. After that, 
cells were fixed using fixative buffer (10 mL formaldehyde, 90 mL PBS, 
and 2 g sucrose) at 37 °C for 15 min and then permeabilized in cold 
methanol at 40 °C for 5 min. Cells were then blocked in 0.5% blocking 
buffer (nonfat dry milk powder in 0.1% phosphate buffered saline with 
Tween 20 (PBST) buffer) at RT for 2 h followed by three washes of 10 min 
with 0.1% PBST. Cells were then incubated with primary antibodies 
at 1:100 dilution in blocking buffer at 4 °C over night separately: Akt 
(Thermofisher) and pAkt (Thermofisher). After three washes of 10 min 
with 0.1% PBST buffer, cells were incubated with 1:800 diluted infrared-
labeled secondary antibody IRDye 800CW (LI-COR) and 1:500 diluted 
CellTag 700 Stain (LI-COR) at RT for 1 h, followed by five washes 
of 10 min with 0.1% PBST. Samples were then dried overnight at RT. 
Infrared signal was detected using an Odyssey infrared imaging system.
Intracellular Signaling Blocking: For PI3K specific inhibition, 
LY-294002 (Sigma-Aldrich) was used at a concentration of 40 × 10−6 m. 
24 h after cell seeding and addition of Fibrin 3D matrix, HLVEC medium 
was supplemented once with LY-294002. After 2 days medium was 
changed normally without further LY-294002 addition until the end of 
culture.
NaBC1 Blocking: For boron transporter blocking, a specific antibody 
was used against a synthetic peptide corresponding to internal amino 
acids 109–123 of human sodium bicarbonate transporter-like protein 11 
(NP_114423.1, SLC4A11), or NaBC1 (abcam).
Cells were seeded, and HLVEC media were supplemented with NaBC1 
antibody at a final concentration of 1 µg mL−1. All medium changes were 
supplemented with antibody when needed until the end of culture.
NaBC1 3D Molecular Modeling: The search for templates in PDB 
database revealed the human erythrocyte band 3 protein SLC4A1 
(Protein bank codes 4YZF and 4KY9 for the cytosolic and the anion 
exchanger domains, respectively) as the best match to model the 
boron transporter named Homo sapiens bicarbonate transporter-related 
protein BTR1 (AF336127.1), with a sequence similarity of around 30%. 
3D-protein structural models were obtained with the SWISS-MODEL 
server in Automated Model. Structural figures were drawn using PyMol 
(https://www.pymol.org). In the absence of a full structural model of 
SLC4A1, the relative positions of the cytosolic and the anion exchanger 
domains were drawn arbitrarily.
Sequence and structural alignment figure of diverse anion 
transporters (AE4, NBC1, NDCBE1, and BTR1) were obtained with 
ClustalX and http://espript.ibcp.fr.
Gene Expression: Total RNA was extracted from HUVEC cultured for 
6 days under different experimental conditions using RNeasy micro kit 
(Qiagen). RNA quantity and integrity was measured with a NanoDrop 
1000 (ThermoScientific). Then 500 ng of RNA was reverse transcribed 
using the Superscript III reverse transcriptase (Invitrogen) and oligo dT 
primer (Invitrogen). Real-time qPCR was performed using Sybr select 
master mix and 7500 Real Time PCR system from Applied Biosystems. 
The reactions were run at least in triplicate for both technical and 
biological replicas. The primers used for amplification were designed 
based on sequences found in the GenBank database and included: 
integrin α5 (NM_002205.4, forward: 5′-GGA CTG TGG AGA AGA CAA 
CAT C-3′, reverse: 5′-GTG AGG TTC AGG GCA TTC TT-3′), integrin 
β1 (NM_002211.3, forward: 5′-ATC CCA TTG ACC TCT ACT ACC 
T-3′, reverse: 5′-GTC CGA AGT AAT CCT CCT CAT TT-3′), integrin αv 
(NM_002210.4, forward: 5′-TAG CAA CTC GGA CTG CAC AAG CTA-
3′, reverse: 5′-AAC CAT TCC CAA AGT CCT TGC TGC-3′), integrin 
β3 (NM_000212.2, forward: 5′-CAT CCA TAG CAC CTC CAC ATA C-3′, 
reverse: 5′-CCA GCC AAC TCA TGG GAA TAA-3′), uPA (NM_002658, 
forward: 5′-GTG GAT GTG CCC TGA AGG A-3′, reverse: 5′-TGC GGA 
TCC AGG GTA AGA AG-3′), uPAR (NM_002659, forward: 5′-CCC AAT 
CCT GGA GCT TGA AA-3′, reverse: 5′-TTG GTT TTT CGG TTC GTG 
AGT-3′), β-actin (NM_001101.3, forward: 5′-CGC CGC CAG CTC ACC 
ATG-3′, reverse: 5′-CAC GAT GGA GGG GAA GAC GG-3′).
The fractional cycle number at which fluorescence passed the 
threshold (Ct values) was used for quantification using the comparative 
Ct method. Sample values were normalized to the threshold value of 
housekeeping gene β-actin: ΔCt = Ct (experiments) − Ct (β − actin). 
The Ct value of the control (B0% substrate) was used as a reference. 
ΔΔCt = ΔCt(experiment) − ΔCt(control). mRNA expression was 
calculated by the following equation: fold change 2 C t= −∆∆ .
NaBC1 PCR detection was performed using AmpliTaq Gold 
360 DNA polymerase (Invitrogen). The primers used for amplification 
were designed based on sequences found in the GenBank database 
(AF336127.1, forward: 5′-CAT GAT CGC CAT GAT CCC CAT CCG-3′, 
reverse: 5′-CAG ATG CCC CAG GCC TGA GTC AGC-3′).
Colocalization Experiments: Colocalization of NaBC1/VEGFR 
experiments was performed using DUOLINK PLA system (Sigma-Aldrich) 
and following manufacturer instructions. Specific primary antibodies 
used were anti NaBC1 (dilution 1:200, abcam) and anti VEGFR (dilution 
1:400, abcam). For image quantification of colocalization fluorescent 
dots, at least 20 individual cells were imaged for each condition under an 
epifluorescence microscope (Nikon Eclipse 80i).
CAM Assay: Chick CAM assay was tested for vascularization potential 
of different boron-loaded materials. Boron-loaded PLLA (solvent casted) 
was previously characterized and it was confirmed that boron does not 
change surface wettability, mechanical properties, or the amount of FN 
adsorbed compared to PLLA.[18]
PLLA, PLLA–B2%, and PLLA–B5% solvent-casted films were 
grafted atop chorioallantoic membrane from embryonic day 8 chicken. 
Chorioallantoic membrane without material was used as control 
condition. Total blood vessels were imaged with a stereomicroscope 
after 96 h of incubation at 37.5 °C.
Image Analysis: The 8-bit monochrome fluorescence images 
corresponding to HUVEC and nuclei 4′,6-diamino-2-fenilindol (DAPI) 
were segmented using an interactive semiautomatic machine-learning 
algorithm with Ilastik 1.2.2. Background and cells were segmented 
and converted to a binary mask in Fiji-ImageJ. The contours were 
softened applying a 3 pixel wide Gaussian blur filter followed by 
a binarization filter. Then, the masks were skeletonized and the 
skeleton parameters were analyzed using the Analyze skeleton plugin 
in Fiji-ImageJ.
For the CAM assay, the stereomicroscope RGB color images were 
enhanced using histogram normalization on the three channels using 
Fiji-ImageJ and the vessels were marked manually to allow segmentation. 
The images with the marked vessels were thresholded to isolate the 
markings from the background and obtain a binary image. The binary 
image was skeletonized and analyzed using the Analyze skeleton plugin 
of Fiji-ImageJ.
The following parameters of the skeletonized binary masks were 
analyzed: junctions, slab pixels, total number of triple points, number 
of cells, total cell area, and percentage of area covered by cells. The 
total number of structures, defined as isolated groups of branches 
in the skeletonized image, was also determined. A minimum of ten 
microscope fields per experimental condition were analyzed.
Statistical Analysis: For statistical analysis, the data were analyzed for 
normality using the D’Agostino and Pearson omnibus normality test 
with an α of 0.05. When the normality test was passed, an ordinary 
one-way analysis of variance (ANOVA) test with a Tukey’s, Sidak’s, or 
Dunnett’s posthoc analysis (p = 0.05) was used to compare the means 
of the columns against the control column. When the normality test 
was not passed, a nonparametric test with a posthoc Dunn analysis 
(p = 0.05) was used to compare the means of each column against the 
control column. Data were represented as mean ± standard deviation 
(SD). Sample size for each statistical analysis was indicated in the 
corresponding figure legends. GraphPad Prism 6 XML software was 
used for statistical analysis.
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